Konstantin Kandybey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Konstantin Kandybey has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Lyudmila I. Kucherenko
Zaporizhzhia State Medical and Pharmaceutical University
2 shared publications - D. A. Sereda
ТОВ НВО «Фарматрон», м. Запоріжжя, Україна
1 shared publication - H. R. Nimenko
Zaporizhzhia State Medical and Pharmaceutical University
1 shared publication I. F. Bielenichev
1 shared publication- K. Yu. Nerianov1 shared publication
- Khromylova Olga Vladimirovna
Запорізький державний медико-фармацевтичний університет, Україна
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 4 (62),p. 48-56
Selection of excipients for the development of an oral powder containing dimethylaminoethanol and sodium succinate
Dimethylaminoethanol (DMAE) and sodium succinate are promising active compounds with demonstrated nootropic and metabolic potential, making their combination a candidate for the development of a novel drug aimed at improving cognitive function and supporting neurometabolic processes. Oral powders in sachet form represent a technologically rational choice for such a formulation, offering precise dosing, stability, and ease of use. However, the development of a high-quality sachet powder requires careful selection of excipients that are fully compatible with the active substances and capable of ensuring optimal physicochemical and organoleptic characteristics of the final product. The aim of the study is to scientifically substantiate and select optimal excipients for an oral powder form containing dimethylaminoethanol and sodium succinate, based on a comprehensive assessment of pharmacotechnological indicators. Materials and methods. Nine powder dosage forms were evaluated using a three-factor Greco-Latin square. Each series containing equal amounts of both active ingredients – dimethylaminoethanol and sodium succinate – in a 1 : 1 ratio. Three levels were studied for each factor: fillers (mannitol, lactose, sucrose), disintegrants/anti-caking agents (croscarmellose sodium, potato starch, magnesium carbonate basic), and solubilizers (PEG 4000, PVP K17, PVP K90). Pharmaco-technological parameters were assessed in duplicate; statistical significance was determined by ANOVA. Results. The optimal formulation – comprising sucrose (86%), magnesium carbonate basic (2%), and polyethylene glycol 4000 (2%) alongside 5% each of the two active substances – demonstrated the best combination of technological performance and consumer acceptability. Conclusions. A rational excipient composition for an oral powder sachet containing dimethylaminoethanol and sodium succinate was established through systematic three-factor experimental design and ANOVA
- 31 August 2026
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 4 (62),p. 48-56
Open AccessSelection of excipients for the development of an oral powder containing dimethylaminoethanol and sodium succinate
Dimethylaminoethanol (DMAE) and sodium succinate are promising active compounds with demonstrated nootropic and metabolic potential, making their combination a candidate for the development of a novel drug aimed at improving cognitive function and supporting neurometabolic processes. Oral powders in sachet form represent a technologically rational choice for such a formulation, offering precise dosing, stability, and ease of use. However, the development of a high-quality sachet powder requires careful selection of excipients that are fully compatible with the active substances and capable of ensuring optimal physicochemical and organoleptic characteristics of the final product. The aim of the study is to scientifically substantiate and select optimal excipients for an oral powder form containing dimethylaminoethanol and sodium succinate, based on a comprehensive assessment of pharmacotechnological indicators. Materials and methods. Nine powder dosage forms were evaluated using a three-factor Greco-Latin square. Each series containing equal amounts of both active ingredients – dimethylaminoethanol and sodium succinate – in a 1 : 1 ratio. Three levels were studied for each factor: fillers (mannitol, lactose, sucrose), disintegrants/anti-caking agents (croscarmellose sodium, potato starch, magnesium carbonate basic), and solubilizers (PEG 4000, PVP K17, PVP K90). Pharmaco-technological parameters were assessed in duplicate; statistical significance was determined by ANOVA. Results. The optimal formulation – comprising sucrose (86%), magnesium carbonate basic (2%), and polyethylene glycol 4000 (2%) alongside 5% each of the two active substances – demonstrated the best combination of technological performance and consumer acceptability. Conclusions. A rational excipient composition for an oral powder sachet containing dimethylaminoethanol and sodium succinate was established through systematic three-factor experimental design and ANOVA
- Open Access
- 3 July 2023
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Current issues in pharmacy and medicine: science and practice
- Vol. 16 (2) , 170-174
The use of Thiocetam in the complex therapy of combat-related brain contusion
Each patient presents a unique set of characteristics and challenges when it comes to acute cerebral ischemia resulting from craniocerebral injury. The aim of this study is to investigate the utilization of Thiocetam as part of a comprehensive treatment approach for combat-related cerebral contusion and to assess the therapeutic effects of Thiocetam in patients with mild and moderate closed combat craniocerebral trauma in comparison to standard basic therapy. Materials and methods. 79 patients with mild and moderate closed combat craniocerebral trauma were examined. Among them, 76 patients experienced craniocerebral trauma due to an explosive blast injury, which included conditions such as brain concussion, mild cerebral contusion, and cranial vault fractures. All patients were admitted to the department during the acute period of their injuries. During the study, various clinical and functional methods were employed to assess the condition of the central nervous system. These methods were used to evaluate the effects of the complex treatment administered to the patients. Results. The administration of Thiocetam to the patients did not result in an increase in excitability, nervousness, or sleep disturbances. Furthermore, the examination of autonomic reactivity following Thiocetam treatment revealed that the indicator of normal autonomic reactivity increased to 60 % in the treated group, whereas it only increased to 42 % in the control group. Additionally, the patients with initially heightened vegetative reactions experienced a decrease from 42.8 % to 17.9 % in the treated group, while the control group saw a decrease from 38.5 % to 23.1 %. In terms of clinical outcomes, a positive effect was observed in 94 % of patients in the Thiocetam-treated group within the first 5 days. In comparison, the control group showed a positive clinical effect in 76 % of cases. This improvement was evident both in the clinical field and based on indicators of autonomic reactivity in EEG data, as well as cognitive function assessed by the MMSE cognitive function test scale. Conclusions. The utilization of Thiocetam during the acute phase of mild and moderate closed combat craniocerebral trauma enhances the neuroprotective effects of basic therapy. The combined drug Thiocetam, which possesses both nootropic and neuroprotective effects, offers the advantage of reducing or even avoiding the side effects commonly associated with traditional racetam nootropics.
- 3 July 2023
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Current issues in pharmacy and medicine: science and practice
- Vol. 16 (2) , 170-174
Open AccessThe use of Thiocetam in the complex therapy of combat-related brain contusion
Each patient presents a unique set of characteristics and challenges when it comes to acute cerebral ischemia resulting from craniocerebral injury. The aim of this study is to investigate the utilization of Thiocetam as part of a comprehensive treatment approach for combat-related cerebral contusion and to assess the therapeutic effects of Thiocetam in patients with mild and moderate closed combat craniocerebral trauma in comparison to standard basic therapy. Materials and methods. 79 patients with mild and moderate closed combat craniocerebral trauma were examined. Among them, 76 patients experienced craniocerebral trauma due to an explosive blast injury, which included conditions such as brain concussion, mild cerebral contusion, and cranial vault fractures. All patients were admitted to the department during the acute period of their injuries. During the study, various clinical and functional methods were employed to assess the condition of the central nervous system. These methods were used to evaluate the effects of the complex treatment administered to the patients. Results. The administration of Thiocetam to the patients did not result in an increase in excitability, nervousness, or sleep disturbances. Furthermore, the examination of autonomic reactivity following Thiocetam treatment revealed that the indicator of normal autonomic reactivity increased to 60 % in the treated group, whereas it only increased to 42 % in the control group. Additionally, the patients with initially heightened vegetative reactions experienced a decrease from 42.8 % to 17.9 % in the treated group, while the control group saw a decrease from 38.5 % to 23.1 %. In terms of clinical outcomes, a positive effect was observed in 94 % of patients in the Thiocetam-treated group within the first 5 days. In comparison, the control group showed a positive clinical effect in 76 % of cases. This improvement was evident both in the clinical field and based on indicators of autonomic reactivity in EEG data, as well as cognitive function assessed by the MMSE cognitive function test scale. Conclusions. The utilization of Thiocetam during the acute phase of mild and moderate closed combat craniocerebral trauma enhances the neuroprotective effects of basic therapy. The combined drug Thiocetam, which possesses both nootropic and neuroprotective effects, offers the advantage of reducing or even avoiding the side effects commonly associated with traditional racetam nootropics.